 |
 |
Cephalon Trading Suspended Pending FDA Meeting 12:03 PM EDT Thursday Nasdaq temporarily halted trading of Cephalon Inc.'s common stock Thursday pending the outcome of a Food and Drug Administration advisory committee meeting on the company's request to expand the approved uses for its narcolepsy drug Provigil. The FDA's Peripheral and Central Nervous System Drugs Advisory Committee is reviewing a supplemental new drug application through which Cephalon, based in West Chester, Pa., wants to market Provigil as a treatment for adults suffering from disorders where excessive sleepiness occurs. Provigil is already widely prescribed by doctors for off-label uses such a treating fatigue in patients with sleep apnea, Parkinson's disease, multiple sclerosis, chronic-fatigue syndrome and depression. Sales of Provigil are expected to top $300 million this year. SOURCE: Philadelphia Business Journal, PA http://tinyurl.com/opxh * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn